Human CXCL12/SDF-1 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF-310-NA
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Neutralization, Western Blot
Cited:
Bioassay, Blocking/Neutralizing, ELISA Development (Capture), Functional Assay, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry-Paraffin, Neutralization, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant human CXCL12/SDF‑1 alpha
Lys22-Lys89
Accession # Q6ICW0
Lys22-Lys89
Accession # Q6ICW0
Specificity
Detects human CXCL12/SDF-1 in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CXCL12/SDF-1 Antibody
Chemotaxis Induced by CXCL12/SDF-1 alpha and Neutralization by Human CXCL12/SDF-1 Antibody.
Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF-1a (Catalog # 350-NS) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF-1a (2 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL12/SDF-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-310-NA). The ND50 is typically 1.5-6.0 µg/mL.Applications for Human CXCL12/SDF-1 Antibody
Application
Recommended Usage
Western Blot
0.1 µg/mL
Sample: Recombinant Human/Feline CXCL12/SDF-1 beta aa 19-93 (Catalog # 2716-SD)
Recombinant Human/Feline CXCL12/SDF-1 beta aa 22-93 (Catalog # 351-FS)
Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF-1 alpha (Catalog # 350-NS)
Sample: Recombinant Human/Feline CXCL12/SDF-1 beta aa 19-93 (Catalog # 2716-SD)
Recombinant Human/Feline CXCL12/SDF-1 beta aa 22-93 (Catalog # 351-FS)
Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF-1 alpha (Catalog # 350-NS)
Neutralization
Measured by its ability to neutralize CXCL12/SDF-1 alpha-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CXCR4. The Neutralization Dose (ND50) is typically 1.5-6.0 µg/mL in the presence of 2 ng/mL Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF-1 alpha.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 2 reviews rated 4 using AF-310-NA in the following applications:
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CXCL12/SDF-1
CXCL12, also known as SDF-1 (stromal cell-derived factor 1) and PBSF (Pre-B cell growth stimulatory factor), is a member of the CXC chemokine superfamily. Two alternatively spliced mRNAs encode CXCL12 alpha (89 aa residues) and CXCL12 beta (93 aa residues) that differ by the addition of 4 amino acids at the carboxy-terminus. Human and mouse CXCL12 are highly conserved. Mature human and mouse CXCL12 differ only by 1 amino acid.
Alternate Names
PBSF, SDF-1, SDF1
Gene Symbol
CXCL12
UniProt
Additional CXCL12/SDF-1 Products
Product Documents for Human CXCL12/SDF-1 Antibody
Product Specific Notices for Human CXCL12/SDF-1 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...